Latest news with #Pharmaceuticals
Business Upturn
18 hours ago
- Business
- Business Upturn
Sun Pharma subsidiaries settle US antitrust litigation for $200 million
Sun Pharmaceutical Industries Limited ('Sun Pharma') has announced that its subsidiaries, Sun Pharmaceutical Industries, Inc. ('SPII') and Taro Pharmaceuticals U.S.A., Inc. ('Taro'), have entered into a settlement agreement with the End Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania, U.S. Under the terms of the agreement, SPII and Taro will make a combined payment of $200 million. In return, all claims brought against them—along with their current and former parents, affiliates, predecessors, successors, directors, officers, employees, and representatives—will be fully released by the settlement class members in the End Purchaser Action. The settlement amount may be reduced if more than a certain percentage of total insured class members opt out of the class. Sun Pharma clarified that the settlement is being entered into without any admission of wrongdoing. The agreement remains subject to court approval. In the meantime, Sun Pharma shares closed at ₹1,692.00 today, after opening at ₹1,682.50. During the session, the stock touched an intraday high of ₹1,696.00 and a low of ₹1,680.10. The stock remains below its 52-week high of ₹1,960.35, while staying comfortably above the 52-week low of ₹1,553.05. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Times of Oman
2 days ago
- Business
- Times of Oman
India's exports remain resilient amidst global challenges
New Delhi: India's trade performance during the first quarter of the financial year 2025–26 reflects a resilient trend amid global economic uncertainty. During the period from April to June 2025, the merchandise exports remained largely stable, services exports surged, and the overall trade deficit narrowed, showcasing India's ability to adapt and thrive in a dynamic global environment. In June 2025, India's merchandise exports stood at USD 35.14 billion as compared with USD 35.16 billion in June 2024, this resilience comes against a backdrop of fluctuating global demand and supply chain constraints. Importantly, 15 of the 30 key export sectors registered positive growth, revealing the inherent strength and diversity of India's export basket. Electronic goods led the performance showed with an impressive 46.93% growth, followed by traditional sectors like tea (32.64%) and jute including floor coverings (23.44%). Other significant contributors included meat, dairy & poultry products (19.7%), marine products (13.33%), and processed food items (8.09%). Pharmaceuticals continued their upward momentum with a 5.95% increase, while engineering goods, fruits & vegetables, chemicals, and textiles also posted moderate gains. These sectoral performances highlight India's gradual transition towards high-value, technology-driven, and processed exports. On the imports front, India reported merchandise imports worth USD 53.92 billion in June 2025, marking a decline of (-)3.71% compared to USD 56.00 billion in June 2024. This contraction is partly the result of lower demand for commodities, ongoing efforts to promote domestic production, and a softening of global prices. Of the 30 major import categories, 17 registered negative growth. The most significant drop was witnessed in the import of pulses, which plummeted by 74.96%, followed by newsprint (-61.66%), gold (-25.73%), and transport equipment (-20.46%). Declines in coal and petroleum products also indicated lower energy demand or increased use of alternative sources. Other sectors such as leather goods, iron & steel, non-ferrous metals, and chemicals also saw reduced import volumes. This pattern suggests a cautious yet strategic consumption environment, with possible implications for industrial production and investment trends. The merchandise trade deficit for June 2025 narrowed to USD (-)18.78 billion from USD (-)20.84 billion a year earlier. This reduction reflects the larger contraction in imports relative to exports, and bodes well for India's current account management. It also demonstrates the government's success in fostering self-reliance across key manufacturing and raw material sectors. While merchandise exports remained steady, the real strength of India's trade in June 2025 came from the services sector. Services exports stood at USD 32.84 billion, marking a healthy year-on-year growth of 14% over USD 28.67 billion in June 2024. This growth is attributable to India's global leadership in IT, business process outsourcing, fintech, consulting, and other knowledge-intensive sectors. Services imports, meanwhile, rose by 16.1% to USD 17.58 billion, reflecting increased payment for technical and professional services as Indian firms engaged with international vendors. Despite this, India maintained a robust services trade surplus of USD 15.26 billion, compared to USD 13.53 billion in the same month last year. Combining merchandise and services, India's overall trade in June 2025 reached USD 139.48 billion, up from USD 134.97 billion in June 2024. More significantly, the overall trade deficit narrowed sharply from USD (-)7.30 billion in June 2024 to USD (-)3.51 billion in June 2025. This narrowing is a positive signal, suggesting that India's economy is increasingly able to balance its external engagements by leveraging its competitive strengths in services while managing commodity and capital goods imports judiciously. A broader view of the April to June 2025 quarter reveals further insights. India's total exports combining goods and services amounted to USD 210.37 billion, compared to USD 198.52 billion during the same period in 2024, marking a 6% overall growth. Merchandise exports showed a modest rise from USD 110.06 billion to USD 112.17 billion, while services exports surged from USD 88.46 billion to USD 98.13 billion, a testament to India's continued success in high-skill sectors and digital exports. Meanwhile, total imports also increased, reaching USD 230.62 billion from USD 220.94 billion in the year-ago quarter. This included merchandise imports of USD 179.44 billion and services imports of USD 51.18 billion. Despite higher imports, India managed to reduce its overall trade deficit to USD (-)20.25 billion in April–June 2025 from USD (-)22.42 billion in the same quarter of 2024. The key driver behind this improvement was the rising surplus in services trade, which expanded to USD 46.95 billion from USD 39.68 billion last year. The data reveals a shifting composition of both exports and imports. The impressive growth in electronics, pharmaceuticals, and processed foods suggests that India's production-linked incentive (PLI) schemes and policy push towards value-added manufacturing are beginning to yield results. Services, especially IT and knowledge exports, remain India's crown jewel in foreign trade, providing not just foreign exchange but also strategic economic leverage. Looking ahead, India's trade outlook appears promising, driven by emerging opportunities in global supply chain diversification, digital trade expansion, and green transition technologies. With geopolitical shifts prompting many countries to reduce dependence on traditional hubs like China, India is well-positioned to emerge as a preferred alternative for manufacturing and services alike. The continued implementation of Production-Linked Incentive (PLI) schemes, investments in semiconductor and electronics manufacturing, and digitization of customs and logistics processes are expected to further enhance export competitiveness. Furthermore, the rising global demand for skilled services in AI, cybersecurity, and digital finance offers India a long-term edge. However, challenges such as volatile commodity prices, trade protectionism, and global economic uncertainty remain. Strategic trade agreements, infrastructure upgrades, and sustained policy focus on ease of doing business will be crucial in ensuring India capitalizes on these future trade possibilities. In conclusion, the first quarter of FY 2025–26 has set an optimistic tone for India's foreign trade. Merchandise exports, while not expanding significantly, have shown sectoral depth and stability. Imports have been prudently managed, and the ever-strong services sector continues to power India's external sector performance. With a narrowing trade deficit, improving export diversity, and growing services surplus, India stands on a firm footing to deepen its integration with the global economy. Strategic policy support, continued investment in digital and manufacturing infrastructure, and targeted export promotion can further enhance India's trade trajectory in the coming quarters.
France 24
3 days ago
- Automotive
- France 24
August 1 deadline for 30% tariffs looms over US-EU trade talks
06:20 From the show Reading time 1 min Trade negotiations between Washington and Brussels are continuing ahead of an August 1 deadline, when US President Donald Trump has vowed to impose 30 percent tariffs on nearly all goods imported from the European Union. Both sides are looking to carve out exemptions for key sectors, such as aviation or pharmaceuticals. Also in this edition: German car sector companies are looking to benefit from the country's sudden increase in defence spending.
Yahoo
7 days ago
- Business
- Yahoo
Guggenheim Maintained a Hold Rating on Johnson & Johnson (JNJ)
Johnson & Johnson (NYSE:JNJ) is one of the . On July 10, Guggenheim analyst Vamil Divan maintained a Hold rating on Johnson & Johnson (NYSE:JNJ) with a price target of $164. The cautious rating comes as the company gets close to releasing its Q2 2025 earnings results. The second quarter 2025 earnings call is scheduled for July 16. The company released its Q1 2025 results on April 15, where it grew its sales by around 2% year-over-year to $21.9 billion. Johnson & Johnson (NYSE:JNJ) achieved strong growth of nearly 6% in the US market, which helped to offset a struggling international market where it experienced a slowdown. A smiling baby with an array of baby care products in the foreground. The main concern for the company remains from a 200% tariff risk by President Trump on Pharmaceuticals. The firm believes the company needs some initiatives aimed at moving away from the tariff risks to improve investor sentiment around the stock. Johnson & Johnson (NYSE:JNJ) is a healthcare company that operates through two segments, including Innovative Medicine and MedTech. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
17-07-2025
- Business
- Yahoo
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan
In connection with HekaBio's recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan. Under Japan's Regenerative Medicine guidelines, cell therapies enjoy a regulatory environment with multiple paths for expedited commercialization. Troculeucel is well positioned to be the first-in-class forerunner for the treatment of several intractable neurodegenerative diseases. SANTA ANA, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ('NK') cell therapeutics, and HekaBio K.K., headquartered in Chuo-ku, Tokyo ('HekaBio'), announced a strategic partnership to accelerate the regulatory, manufacturing and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan following HekaBio's recently announced investment in common equity of NKGen. HekaBio will lead all clinical trials in Japan and oversee all regulatory activities with Japan's Pharmaceuticals and Medical Devices Agency for pre-market approval of troculeucel in several neurodegenerative disease indications, including Alzheimer's and Parkinson's Diseases. As troculeucel is an autologous, non-genetically modified cell therapy, there is allowance under regenerative medicine regulations in Japan to offer this therapy to patients on an accelerated path, much faster than in other major markets. HekaBio will fully leverage the regulation and its domestic strategic partner network, aiming for first dosing in Japanese patients over the next 12 months. Beyond intractable disease, troculeucel has the potential to also support Japan's aging population in the longevity/wellness space. 'Japan has always had an advanced progressive health care system where great attention has been placed on the use of novel autologous cell therapies for prevention, longevity, and wellness as well as for the treatment of more chronic illnesses,' said Paul Y. Song, MD, Chairman and Chief Executive Officer ('CEO') of NKGen. 'I am convinced that HekaBio's clinical, regulatory, and commercial expertise will guide us to satisfy all regulatory requirements, find the best local manufacturing partner to make our therapy readily available, and ultimately develop the best commercial strategy for Japan. We are very excited to partner with HekaBio.' 'Dementia, particularly Alzheimer's Disease, and other neurodegenerative diseases together present significant health and social challenges in Japan due to the country's aging population. We are very excited about our partnership with NKGen and look forward to advancing troculeucel for the benefit of patients and society,' said Rob Claar, CEO of HekaBio. About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit About Troculeucel Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market. About HekaBio HekaBio is a Japan-based healthcare platform that accelerates patient access to global medicines and MedTech across Asia-Pacific. HekaBio reviews over 200 assets annually to in-license a select few, focusing on early-stage yet de-risked opportunities in CNS, oncology and healthy longevity. HekaBio synchronizes U.S. and Japan development timelines and leverages strategic partnerships to optimize commercial success. Japan, the world's third-largest healthcare market, serves as its launchpad for regional expansion. To learn more about HekaBio's mission and portfolio, please visit Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact: Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@ External Contact: Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@
